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Accumulated evidence gathered over recent decades demonstrated that some members of the Parvoviridae family,
in particular the rodent protoparvoviruses H-1PV, the minute virus of mice and LuIII have natural anticancer activity
while being nonpathogenic to humans. These studies have laid the foundations for the launch of a first phase I/IIa
clinical trial, in which the rat H-1 parvovirus is presently undergoing evaluation for its safety and first signs of efficacy
in patients with glioblastoma multiforme. After a brief overview of the biology of parvoviruses, this review focuses on
the studies which unraveled the antineoplastic properties of these agents and supported their clinical use as
anticancer therapeutics. Furthermore, the development of novel parvovirus-based anticancer strategies with enhanced
specificity and efficacy is discussed, in particular the development of second and third generation vectors and the
combination of parvoviruses with other anticancer agents. Lastly, we address the key challenges that remain towards a
more rational and efficient use of oncolytic parvoviruses in clinical settings, and discuss how a better understanding of
the virus life-cycle and of the cellular factors involved in virus infection, replication and cytotoxicity may promote the
further development of parvovirus-based anticancer therapies, open new prospects for treatment and hopefully improve
clinical outcome.
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The idea to use viruses as tools for cancer therapy arose
as early as at the turn of the 20th century, when it was
reported that leukemia patients who contracted influ-
enza went into clinical remission. Although anecdotal,
these observations prompted intensive investigation of
treatment strategies based on viruses with inherent anti-
cancer activity, leading to the launch of the first clinical
trials in the 1950s and 60s. Despite early promise, con-
cerns regarding safety and a lack of efficacy caused a di-
minishment in oncolytic virotherapy research during the
years that followed. However, with dramatic advances in
our understanding of molecular biology and virology
and the advent of genetic engineering, the last two de-
cades have brought with them a resurgence of interest in
the field (for a review on the history of oncolytic vir-
otherapy see [1]). Virotherapeutics can be subdivided* Correspondence: j.rommelaere@dkfz.de
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unless otherwise stated.into two groups: (i) replication-deficient virus vectors,
which are used to deliver therapeutic genes to the target
tumor, and (ii) replication-competent oncolytic viruses
(OVs). The latter possess the ability to selectively infect,
replicate in and destroy tumor cells, while sparing their
normal counterparts. In addition to their direct oncolytic
effect, OVs induce antitumor immune responses. Im-
portantly, the balance between antitumor and antiviral
immune reactions plays a major role in the efficiency of
OV-mediated tumor suppression. Figure 1 summarizes
major advantages and limitations of oncolytic virother-
apy. For a general introduction to the field we redirect
the readers to these excellent recent reviews [2,3]. As a
result of their oncosuppressive abilities demonstrated in
numerous preclinical models, no fewer than twelve OVs
are currently being evaluated in clinical trials against a
number of different cancers. In particular, a modified
herpes simplex virus (HSV) (OncoVEX GM-CSF) [4]
and reovirus (Reosyn, Reolysin) [5] have reached phase
III clinical trials against recurrent melanoma and head
and neck cancer, respectively, and a recombinant vaccinial. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Pros and cons of oncolytic virotherapy. Illustrated are the main advantages of oncolytic virotherapy and the major challenges that
remain to be tackled in order to improve clinical outcome.
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in a randomized phase IIb clinical study against recurrent
hepatocellular carcinoma [6]. Results are very promising
and there is a justified optimism that these agents may be
approved by the regulatory agencies in the near future and
become real therapeutic options for cancer patients with
these diseases. Among OVs, the Rodent protoparvovirus 1
(RoPV) species within the Parvoviridae family deserves
special consideration for its promising anticancer proper-
ties. The RoPV viruses exert striking oncosuppressive ef-
fects in various preclinical tumor models, are able to kill
tumor cells which resist conventional treatments, and have
not been associated with disease in humans, laying the
basis for the launch of the first phase I/IIa clinical trial
using the rat oncolytic H-1 parvovirus (H-1PV).
Basic characteristics of oncolytic parvoviruses
Classification
The Parvoviridae family presently includes 134 viruses
that infect a broad range of hosts. They are character-
ized by an icosahedral capsid of about 25 nm in diam-
eter containing a linear, single-stranded DNA molecule
[7]. The family is divided in two subfamilies, Parvoviri-
nae and Densovirinae, members of which infect verte-
brates and arthropods, respectively [7]. Eight genera
have been classified as belonging to the Parvovirinae
subfamily. The focus of the present review is on one of
these genera, Protoparvovirus, and more particularly on
one of its species, Rodent protoparvovirus 1 (RoPV1),
whose members are able to replicate autonomously in
close dependence on cellular S-phase factors. RoPVs in-
clude the H-1 parvovirus (H-1PV), the major subject of
this review, the Kilham rat virus (KRV), the LuIII virus,the Mouse parvoviruses (MPV) and the Minute viruses of
mice (MVM). In unprotected fetuses and neonates of the
natural or related hosts, RoPV infection can be pathogenic
and even lethal, whilst in adults the infection is clinically
inapparent though persistent. Interestingly, these viruses
are able to replicate in cells of different origins, including
transformed human cells, as it will be extensively discussed
in the next paragraphs.
Rodent protoparvovirus structure and products
The RoPV capsid consists of 60 copies of two to three poly-
peptide sequences represented by the capsid proteins VP1,
VP2 and VP3 [8]. The capsid structure is characterized by
three main elements: (i) a spike-like protrusion at the 3-fold
axis of symmetry; (ii) a depression, called dimple, at the
2-fold axis; (iii) a pore located at the 5-fold axis, connecting
the inside of the virion to the exterior [9] (Figure 2A).
The parvoviral genome is a linear, single-stranded
DNA molecule of around 5 kb comprising two tran-
scription units that respectively code for non-structural
proteins (NS) involved in the replication process and in
viral cytotoxicity, and structural proteins (VP) forming
the capsid. The expression of viral genes is regulated by
two promoters, P4 and P38 [10]. P4 controls the expres-
sion of the non-structural proteins NS1, NS2 (and a pu-
tative NS3 read-through product). P38 regulates the
production of the capsid proteins VP1 and VP2 (and of
a minor regulatory protein called SAT) and is transacti-
vated by the NS1 protein. At both termini of the viral
DNA, coding sequences are flanked by short terminal
palindromes, whose size varies between the left (approx.
120 nt) and the right (approx. 250 nt) terminus, and
which are essential for the replication process (Figure 2B).
Figure 2 The oncolytic rat parvovirus H-1PV. A) A model of the
icosahedral capsid is illustrated showing the 2, 3 and 5 fold axes of
symmetry [28] B) The 5 kb single-stranded linear DNA genome has
unique palindromic terminal sequences (Pal) that serve as self-priming
origins of replication. Transcription is regulated by the P4 and P38
promoters, whose position is indicated by arrows. There are two
transcription units coding for the non-structural (NS) and structural (VP)
proteins, respectively.
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phosphoprotein of 672 amino acids with a theoretical
molecular weight of 83 kDa. It is mainly located in
the nucleus due to a nuclear localization signal (NLS)
within its sequence [11], although a minor but signifi-
cant fraction of the protein remains cytoplasmatic. NS1
contains a DNA-binding domain in the N-terminal region
[12] and a transcriptional activation domain located at the
C-terminus, responsible for the regulation of the P38 pro-
moter and of its own P4 promoter activities [8]. NS1 binds
to the viral genome as homodimers or multimers, confor-
mations promoted by ATP.
NS1 plays a major role in the RoPV life cycle, regulating
both viral DNA replication and gene expression. It has
been shown that NS1 is target for post-translational modi-
fications that regulate protein functions. For instance,
phosphorylation on different amino-acid residues cata-
lysed by cellular protein kinases C (PKC), regulates both
enzymatic (helicase and ATPase) and non-enzymatic
(DNA binding and transcriptional activation) NS1 activ-
ities [10]. Furthermore, recent studies have described that,
in addition to phosphorylation, acetylation also plays animportant role in modulating the cellular activities of the
H-1PV NS1 protein and in particular the ability of the
protein to bind to DNA, to transactivate the P38 promoter
and regulate viral replication [13].
Besides being involved in the regulation of the parvo-
viral life cycle, as will be discussed in the next paragraphs,
NS1 is also the major effector of viral cytotoxicity and its
sole expression is sufficient to induce cell cycle arrest and
apoptosis [14-16].
The RoPV protein NS2 has a molecular mass of about
25 kDa and a mainly cytoplasmic localization. In the
case of MVM and related viruses, alternative splicing
produces three different isoforms, NS2Y, NS2L and
NS2P. The exact role of NS2 in the viral life cycle and
cytotoxicity is still elusive. However, studies performed
in mouse cells infected with MVM demonstrated a role
of NS2 in the synthesis of DNA replicative forms and
progeny production [8]. Furthermore, it has been shown
that the interaction of NS2, through a nuclear export se-
quence, with chromosome region maintenance protein 1
(CRM1) is required for efficient nuclear egress of pro-
geny virions in mouse cells [17].
Recently, a novel non-structural protein has been identi-
fied, namely the small alternatively translated (SAT) pro-
tein, which is conserved among all members of the
Protoparvovirus genus [18]. The open reading frame of this
protein is located a few nucleotides downstream of the VP2
initiation codon. The protein localizes to the endoplasmic
reticulum (ER) in Porcine parvovirus-infected cells and,
although its role during infection remains elusive, it has
been suggested to block major histocompatibility complex
(MHC) type I processing and/or trigger ER stress-induced
cell death, similarly to other ER-targeted viral proteins [18].
The structural proteins VP1 and VP2 present the same
nucleotide sequence except for the N-terminal domain:
VP1 contains a unique sequence of 140 to 230 residues,
besides the complete sequence of VP2. These additional
residues have been shown to be important for viral in-
fectivity but not for the packaging process [19,20]. The
VP1 unique region displays a phospholipase A2 (PLA2)
activity, which is conserved among Parvovirinae mem-
bers and thought to be required for the transfer of viral
genomes from the endocytic compartment to the cytosol
[21-24]. VP2 is the most abundant protein of the capsid
representing 90% of the entire structure. VP3 is gener-
ated by post-assembly proteolytic cleavage of 25 amino
acids at the N-terminus of VP2 and is found only in
small amounts in infectious particles [25].
Protoparvovirus entry, replication and egress
Virus entry into target cells occurs through the inter-
action of the viral capsid with surface cellular receptors,
which have been identified only for some members of
the Parvovirinae subfamily. For instance, the Feline and
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virus, require the transferrin receptor for the entry process
[26]. Regarding the Rodent protoparvovirus species, sialic
acid has been identified as an important mediator for cell
membrane recognition and entry for the MVM and H-1PV
viruses [27-29], though the cognate cell receptors remain to
be identified.
Viral capsids enter target cells through an endocytic
mechanism, which is thought to involve clathrin proteins
[30], and transports virions to perinuclear regions
[25,31,32]. The PLA2 activity of the VP1 protein triggers
the degradation of the endosome by modification of its
membrane composition, thereby favoring the release of
viral particles into the cytoplasm [21-24]. The intracellular
trafficking of viral particles mainly involves the micro-
tubule network [33] and viral entry into the nucleus occurs
through the nuclear pore complex (NPC). The interaction
of the virus with proteins of the NPC has been shown to
lead to the exposure of the unique sequence of the VP1
viral protein containing nuclear localization signals (NLS)
besides the PLA2 domain. In some experimental systems,
Protoparvovirus members have proven able to induce dis-
ruption of the nuclear envelope through activation of key
enzymes of mitosis [34]. However, this nuclear breakdown
process is unlikely to be the normal pathway of viral entry
into the nucleus during infection of most cells. Protoparvo-
virus genome replication is strictly dependent on S-phase
cellular factors. Therefore, incoming virions remain silent,
without integrating their DNA into the cellular genome,
until the host cell enters S-phase. As the cell expresses
S-phase factors, viral DNA replication initiates. The repli-
cation process comprises the conversion of the single-
stranded DNA molecule into a double-stranded replicative
form. The newly synthesized double-stranded DNA mole-
cules are used as templates for viral mRNA synthesis and
for the formation of multimeric double-stranded interme-
diates and progeny DNA molecules [8]. Viral genome rep-
lication occurs in well-defined nuclear structures called
“autonomous parvovirus-associated replication (APAR)
bodies and requires the recruitment of cellular factors such
as replication protein A (RPA), proliferating cell nuclear
antigen (PCNA), DNA polymerase α and δ and cyclin A
[35,36]. Subsequent activation of the P4 promoter and ex-
pression of NS1 and NS2 proteins rely on the cellular tran-
scription factors E2F, ATF/CREB, ETS and NF-Y which are
overexpressed in fast replicating cells [10,37]. These vari-
ous factors mediate at least in part the RoPV dependence
on cellular proliferation and transformation. MVM and
H-1PV infection is associated with the induction of a DNA
damage response (DDR) and consequent cell cycle arrest
(see below) [16,38]. It has been proposed that virus-
induced cell cycle arrest perpetuates conditions favorable
for virus replication [16,39]. NS1, in turn, activates the P38
viral promoter, inducing the expression of VP capsidproteins, and guides the DNA replication and encapsida-
tion processes. These steps of the parvoviral life cycle in-
volve the direct interaction of NS1 with various cellular
factors, including RPA and the transcription factors TBP,
TFIIA and SP1/3 [10]. This virus-cell interplay ensures the
progression of viral replication and gene expression on the
one hand, and disturbs cellular metabolic processes on the
other hand [10].
After the expression of the capsid proteins, new virions
are produced and released, most likely through an active
mechanism which brings the progeny virions from the nu-
cleus to the cell periphery. Indeed, it has recently been re-
ported that RoPV egress from the host cell occurs through
the formation of virus-containing cellular vesicles in the
endoplasmic reticulum, which are then transported to the
membrane through the Golgi in a gelsolin-dependent man-
ner [40]. Transport from the endoplasmic reticulum to the
Golgi is mediated by cellular proteins such as moesin and
radixin and seems to be an important step in virus infec-
tion, during which parvoviral particles undergo post-
assembly modifications that increase the infectivity of the
progeny virions. Furthermore, the vesicular transport has
been proven to accelerate release and spreading of the viral
particles [41].
Rodent protoparvovirus-induced cell cycle arrest
The rodent protoparvoviruses MVM and H-1PV have the
ability to induce cell cycle arrest in permissive cells - a
process which is thought to favor viral replication
[15,16,38,42]. The mechanisms underlying MVM-induced
cell cycle arrest have been elucidated in part. During
MVM infection, the NS1-mediated recruitment of cellular
factors involved in viral DNA replication in APAR bodies
leads to the shutoff of cellular genome replication and
subsequent appearance of stalled replication forks [43]. As
a consequence, MVM elicits a cellular DDR which is char-
acterized by recruitment in the APAR bodies of compo-
nents of the DNA damage machinery, such as H2AX,
Nbs1, RPA32, Chk2, p53 and ATM [44]. This results in
cell cycle arrest that, in the case of MVM, occurs in S/G2
phase, depending on the cell type and experimental condi-
tions. While viral DNA and NS1 protein are required for
the induction of the DDR, NS2 is dispensable, as infection
of A9 cells with a MVM mutant lacking NS2 triggered a
similar DDR response to the wild type (wt) virus [45].
Ectopic expression of NS1 was associated with increased
levels of yH2AX phosphorylation, a DNA damage marker,
although levels were much lower than those observed in
virus-infected cells [44]. NS1 overexpression was also
shown to induce cell cycle arrest but the mechanisms
underlying this event may differ from those activated by
the entire virus as the block in addition to S and G2, also
occurs in G1 phase [15,38,46]. It has also been reported
that the expression of NS1 is associated with single-
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DNA replication [46].
The components of the DNA damage machinery
which relocate into the APAR bodies are present in their
active phosphorylated form. The ataxia telangiectasia
mutated protein (ATM), a key regulator of the DNA
damage checkpoint, is the kinase involved in the phos-
phorylation of these factors, as treatment with specific
ATM inhibitors reduces phosphorylation [44]. Import-
antly, ATM-mediated DDR signaling participates in both
the maintenance of MVM-induced cell cycle arrest and
the regulation of virus multiplication, as inhibition of
ATM activity affected both events [44]. Altogether these
results provide evidence that cell cycle arrest is required
for efficient virus multiplication. The importance of ATM
signalling in MVM-induced cell cycle arrest was further
corroborated by the finding that Chk2, a target of ATM
phosphorylation, in MVM-infected cells, mediates the pro-
teosomal degradation of CDC25A, a phosphatase required
for cell cycle progression [47]. Moreover, MVM-induced
cycle arrest is also characterized by cyclin B1 depletion, in
a manner that is dependent upon the DDR response path-
way [47]. As a consequence of DDR induction, p53 is also
up-regulated in murine cells infected with MVM, and most
likely contributes to the cell cycle arrest observed. Interest-
ingly, despite p53 activation, protein levels of the cyclin
kinase inhibitor (CKI) p21, a transcriptional target of p53,
remain low during MVM infection. The virus itself induces
p21 depletion through CRL4Cdt2 E3-ubiquitin ligase,
which also re-localizes to MVM-APAR bodies. PCNA, a
factor required for MVM-replication, functions as a scaf-
fold protein for the p21/CRL4Ctd2 E3-ubiquitin ligase
interaction and degradation [39]. Degradation of p21 is
necessary for efficient virus replication, as the protein
would otherwise negatively interfere with this process by
interacting with and inhibiting PCNA and the CDK-2 [42].
These results demonstrate the ability of MVM to hijack, at
multiple levels, the DDR and the cell cycle machinery to
reshape the cellular milieu and redirect it towards a more
efficient replication.
H-1PV also has the ability to induce a DDR, which re-
sults in a G2/M cell cycle arrest. However the underlying
mechanisms are less well characterized than for MVM. We
have described that virus infection is associated with accu-
mulation of reactive oxygen species (ROS). ROS, which are
a known source of DNA damage, contribute, at least in
part, to both virus-induced DDR and cell cycle arrest, as
antioxidant treatment protected the cells from these events
[16]. Interestingly, the sole expression of NS1, similarly
to the entire virus, is sufficient to trigger ROS accumu-
lation, DNA damage and G2/M cell cycle arrest while,
UV-irradiated virions, that lost the ability to express
this protein, failed to alter cell cycle distribution [16].
These results indicate that NS1 plays a major role inH-1PV-induced cell cycle arrest. How exactly the protein
induces ROS, however remains to be determined.
Rodent protoparvovirus-induced cell death
Cell cycle arrest leads to cell death and, eventually, to
cell lysis. Rodent protoparvoviruses can kill cancer cells
through different mechanisms. Virus-induced apoptosis
has been reported in several cell lines [13,16,48-51], and
is further supported by the fact that cellular regulators
of both intrinsic and extrinsic apoptotic pathways are
subjected to modulation upon parvovirus infection [10].
In addition to their role in regulating cell cycle arrest,
ROS are important mediators of H-1PV-induced apop-
tosis, as antioxidant treatment, leading to a reduction of
ROS levels, also decreased the fraction of cells undergo-
ing apoptosis [16]. In glioma-derived cell lines, however,
H-1PV induces apoptosis in only a small fraction of gli-
oma cells and triggers instead an alternative cell death
pathway involving the relocation of active cathepsins B
and L from lysosomes into the cytosol and the downregu-
lation of cystatin B and C levels, cystatin Band C (two
cathepsin inhibitors) levels [52]. Interestingly, through this
mechanism, H-1PV is able to circumvent the resistance of
some glioma cells to apoptosis-inducing agents, thereby
providing an alternative and efficient way to exert its
oncolytic effect. Necrosis has also been observed as a con-
sequence of RoPV infection [53,54]. As mentioned above,
the non-structural viral protein NS1 plays a central role in
the induction and regulation of the cytotoxic effects asso-
ciated with parvovirus infection. The molecular mecha-
nisms involved in NS1-mediated cell killing are still under
investigation. However, some cellular partners and/or tar-
gets of NS1 have been identified, suggesting hypothetical
pathways through which the parvoviral protein may in-
duce cytotoxic effects. Protein kinase II (CKII) has been
identified as an interaction partner of NS1 in MVM-
infected cells, and it seems that NS1 cytotoxic activities
correlate with the formation of a complex with CKII, since
CKII knock-down is associated with cell resistance to virus
oncolysis [55]. The NS1-CKII complex is involved in the
phosphorylation of components of the cytoskeleton, in
particular specific tropomyosin isotypes, leading to the re-
arrangement and degradation of tropomyosin filaments.
This and other alterations of the cytoskeleton structure
appear to contribute to virus-induced cytotoxicity [10].
For efficient parvoviral multiplication to take place, it is
important that the death of the target cancer cell does not
precede virus genome replication and production of progeny
virions. The NS1-mediated activation of the cellular PDK1/
PKB survival pathway may be one of the mechanisms
evolved by the virus in order to delay host cell death [56].
Importantly, neither virus infection, nor the ectopic
overexpression of the NS1 protein, is able to kill most
normal cells [57,58]. This is believed to be related to a
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differences between normal and tumor cells in the occur-
rence of NS1 post-translational modifications that control
NS1 activities. Some of the cellular factors mediating these
modifications (for instance, PKC isoforms shown to stimu-
late the replicative and cytotoxic functions of NS1 through
phosphorylation of specific NS1 residues) are generally
up-regulated in cancer cells, which may sensitize these
cells (compared with their normal counterparts) to virus-
induced killing [10]. Therefore, the natural oncolytic activity
of RoPV viruses can be traced back to the fact that cancer
cells provide a more favorable intracellular milieu to both
produce and activate viral cytotoxic effectors.
Rodent protoparvoviruses as oncolytic agents
General features of oncolytic parvoviruses
Although RoPV viruses were frequently isolated from
tumor cells, in vitro and in vivo studies have shown that
these agents do not possess any tumorigenic activity but,
on the contrary, exhibit the capacity to interfere with
tumor growth [10,59]. Among RoPVs, the best charac-
terized in terms of antineoplastic activity are the closely
related MVM, LuIII and H-1PV which have the ability
to infect various transformed cell lines of human origin.
Several aspects of their biology make RoPVs particularly
attractive agents for the development of anticancer strat-
egies: (i) viral infection is asymptomatic and not associated
with any disease in adults; (ii) there is a lack of pre-
existing antiviral immunity in the human population; (iii)
they display oncotropic, oncolytic and oncosuppressive
properties, and (iv) they are able to elicit robust anticancer
immune responses [59]. Indeed, MVM, LuIII and H-1PV
are endowed with a natural preference to efficiently infect
and kill tumor cells, while sparing normal cells. As
described above, RoPVs can efficiently kill cancer cells by
activating multiple cell death pathways, making unlikely
the possibility of cancer cells acquiring resistance to viral
cytotoxicity. On the contrary, there are examples in the lit-
erature describing an ability of the virus to overcome and
efficiently kill cancer cells which are resistant to conven-
tional and targeted therapy. Importantly, as will be dis-
cussed more extensively in the next paragraph, the virus,
through lysis of the cancer cell, has the ability to elicit anti-
cancer immune responses that contribute to the elimin-
ation of cancer cells, including those that were not directly
infected by the virus.
RoPV oncoselectivity is not related to inefficient virus
uptake by normal cells, but rather is due to the high de-
pendence of the viral life cycle upon cellular factors that
are dysregulated in tumor cells and involved in the control
of cell proliferation and differentiation (see above).
However, the presence of cellular helper functions is not
the only pre requisite that determines the permissiveness
of target cancer cells for RoPV infection. Indeed, theinactivation of antiviral immune mechanisms may also
contribute to the efficacy of virus infection. In mouse cells,
MVM proved to be sensitive to type I interferon-mediated
defence mechanisms [60]. Cancer cells are often deficient
in their ability to mount this antiviral response, which
may represent an additional factor in their sensitization to
RoPV infection. Furthermore, it was shown that MVM is
able to activate an antiviral cellular immune response in
normal, but not in transformed mouse cells. While trig-
gering the production of type I interferons (IFN-α/β) in
normal mouse fibroblasts, thereby inducing an antiviral
state, MVM activates an evading mechanism by blocking
interferon synthesis in their transformed counterparts
[60]. While RoPVs also fail to evoke a detectable IFN-β
response in human cancer cells, the role of such an eva-
sion process is presently disputed [61]. Besides enhanced
production, the activity of the NS1 viral protein is also
stimulated in transformed cells. For reasons yet unknown,
NS1 exerts its cytotoxic effects in oncogene-transformed
cells, but not in normal ones [62]. This qualitative modula-
tion contributes additionally to the oncoselectivity of RoPV
replication and lytic activity.
Activation of an anticancer immune response by oncolytic
parvoviruses
As for other oncolytic viruses, the antineoplastic effects
of RoPVs are due to direct oncolysis and/or to indirect
immune reactions activated upon virus infection. These
two events are not mutually exclusive, but most likely
cooperate to achieve virus-mediated oncosuppression.
H-1PV infection of tumor cells stimulates the expression
of danger- and pathogen-associated molecular patterns
(DAMPs and PAMPs) and the release of tumor-associated
antigens, thereby promoting the cross-presentation of tumor
antigens by immature dendritic cells and facilitating the rec-
ognition of the tumor by the immune system [63]. The im-
munogenic features of RoPV-induced cell death were
demonstrated in various systems including melanoma
[64], glioma [63], and pancreatic cancer [65]. Further-
more, H-1PV was recently shown to induce pancreatic
and colon carcinoma cells to display ligands to activat-
ing receptors of natural killer (NK) cells, resulting in
enhanced NK cell-mediated killing of these cancer cells
[66]. The immunostimulatory effect of RoPVs plays a signifi-
cant role in their oncosuppressive activity. The occurrence
of this immune component was evidenced by immunode-
pletion [67], immunoreconstitution [68] and immunostimu-
lation [69] experiments. Further in vivo studies, performed
in immunocompetent rats bearing two pancreatic tumors
implanted at distant sites, showed that, when H-1PV was
injected at only one tumor site, regression of the tumor
located at the distal site could be observed. This bystander
effect is believed to be mediated by the immune system as a
result of its virus-dependent activation at the injected site,
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forin at the distal tumor site [59]. The immune component
of RoPV oncosuppression was also demonstrated through
adoptive transfer of immune cells. Splenocytes transferred
from immunocompetent rats bearing H-1PV-treated ortho-
topic pancreatic tumors to rats bearing the same, but unin-
fected, tumors were found to protect the recipient animals
from developing cancer, providing evidence that activation
of an antitumor immune response occurs upon H-1PV in-
fection [70]. The induction of an antitumor immune re-
sponse by H-1PV correlates with both stimulation of IFN-γ
production, and increase in the T helper cell population, as
demonstrated in splenocytes from infected tumor-bearing
animals, as well as in human peripheral blood mononuclear
cells (PBMC) infected in vitro [60]. Altogether, these results
provide strong evidence that H-1PV treatment triggers an
antitumor immune response contributing to the success of
cancer virotherapy.
On the other hand, an antiviral humoral immune re-
sponse, and more specifically a production of virus-
neutralizing antibodies, was detected in animal models
within one week after infection with H-1PV, MVM or
the Mouse parvovirus MPV-1 [67,71,72]. Neutralizing
antibodies are expected to impede virus propagation and
ensuing oncosuppression. It is noteworthy in the context
of clinical applications of RoPVs, that no or little seroposi-
tiveness to these agents can be detected in the human
population [73], providing a window between treatment
and seroconversion for unimpeded viral activity. The cap-
acity of RoPVs to elicit antiviral cellular immune responses
is less clear [71] but deserves consideration. However, the
interference of these cellular antiviral responses with
tumor suppression is not necessarily negative and may
actually play a key role in the efficacy of oncolytic vir-
otherapy. For example, in an intracranial murine model
of metastatic melanoma, the virus-specific cytotoxic lympho-
cyte response was shown to be critical to neuroattenuated
HSV-mediated tumor suppression [74]. Similarly, in a B16
melanoma model, the efficiency of vesicular stomatitis virus
(VSV)-induced oncolysis was strongly dependent on virus-
specific NK and CD8 Tcells [75].
Preclinical studies supporting the use of oncolytic
parvoviruses as anticancer agents
In this paragraph, special emphasis will be given to H-1PV
that has been evaluated extensively at the preclinical level
as an anticancer agent using a number of different in vitro
and in vivo tumor models, as summarized in Table 1.
(i) Glioma
Glioblastoma multiforme (GBM) is the most common
and aggressive type of primary brain tumor in humans,
for which the median survival is 15 months after initial
diagnosis [76]. New therapeutic approaches are urgentlyneeded since the current treatments, represented
by surgery, chemo- and radio-therapy, are not
effective against this type of tumor. Glioblastoma
and gliosarcoma-derived cell lines were shown to be
permissive for H-1PV replication and gene expression
and to be highly susceptible to H-1PV-induced
cytotoxicity [77]. The efficiency of H-1PV-mediated
killing of cultured human glioma cells prompted
investigations of the anti-glioma effects of this virus
in vivo. Upon intratumoral or intravenous delivery into
rat orthotopic models of rat or human gliomas, H-1PV
was able to induce complete tumor regression and to
increase animal survival without causing inflammation
or alteration of surrounding normal tissues [78]. Virus
infection was associated with cathepsin B induction in
the tumor but not in normal tissues, substantiating
in vitro evidence that H-1PV induces a lysosomal type
of glioma cell death [79]. Intranasal administration of
H-1PV is also an efficient route of virus delivery in the
case of brain tumors, as demonstrated by viral replication
and spreading at the tumor site [80].
Interestingly, a combination approach using ionizing
radiation and H-1PV showed increased cytotoxicity
in a set of glioma-derived cell lines, including radio-
resistant cells, compared to treatment with single
agents. This effect could be observed more particularly
when infection was performed after irradiation, and
was associated with an increase in both NS1 levels
and S-phase cell fraction. Importantly, this study
demonstrated that previous exposure of glioma cells
to radiation does not affect their susceptibility to
H-1PV infection, supporting the potential clinical use of
H-1PV in pre-irradiated glioma patients [78]. Recently,
twelve different Protoparvovirus members, including
H-1PV, LuIII and MVM, were compared for their
efficacy in killing a panel of glioma-derived cell lines.
LuIII and H-1PV showed the greatest oncolytic
activity when cells were infected with high multiplicities
of infection (MOIs), while LuIII displayed superior
anticancer activity when viruses were used at low
concentrations, with an ability to propagate efficiently
in all glioma cell lines tested. Interestingly, LuIII
reduced tumor growth in mouse xenograft models when
administrated both intratumorally and systemically, with
no apparent adverse side effects for the animals [81].
(ii) Neuroectodermal tumors
H-1PV oncolysis has also been reported in paediatric
neuroectodermal tumors, such as neuroblastoma and
medulloblastoma. Neuroblastoma is a highly malignant
solid tumor originating from the central nervous
system and is characterized by N-myc gene amplifica-
tion, which is a biomarker of poor prognosis. Screening
11 neuroblastoma-derived cell lines for H-1PV sensitiv-
ity showed oncolytic effects in all the
Table 1 Antineoplastic effects of H-1PV on different human tumor entities








Wistar rats; Nude rats
Complete tumor regression
and increased animal survival
[77,79]
Neuroblastoma Cell lines Highly efficient cell
killing
N.D. N.D. [48]





80-100% cell death SCID mice Tumor regression and significant
prolongation of animal survival
[85]
Breast Cell lines and
primary cells







20-100% cell killing SCID mice; Nude rats Tumor regression [13,91]
Cervical
carcinoma
Cell lines 40-100% cell lysis SCID mice; Nude rats Tumor regression [13,96]
Gastric tumors Cell lines 20-80% cell death Nude mice Inhibition of tumor formation [98]
Melanoma Cell lines Cell killing N.D. N.D. [64]
Hepatoma Cell lines 80% reduction of
metabolic activity
Nude mice Inhibition of tumor formation [99]
Colon Cell lines Limited virus replication
and cytotoxicity
N.D. N.D. [66,102]
N.D. Not determined; EBV, Epstein-Barr virus.
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N-myc amplification status. Cytotoxic effects were
associated with efficient viral replication, gene
expression, production of progeny virions and
induction of cell cycle arrest and apoptosis [48].
Interestingly, neuroblastoma-derived cell lines were
especially susceptible to H-1PV oncolysis, supporting
the concept of using H-1PV as an anticancer agent
against this tumor entity.
Medulloblastoma is the most common malignant
brain tumor in children, while in adults its occurrence
is rare. The potential of oncolytic virotherapy for
the treatment of medulloblastoma is supported by
the ability of several oncolytic viruses (Seneca Valley
virus, reovirus and recombinant measles virus) to
efficiently target this tumor type [82,83]. In a recent
study, H-1PV was shown to be cytotoxic for a range
of medulloblastoma-derived cell lines. Interestingly,
virus-induced repression of genes which are involved
in the maintenance of the neural progenitor state
(including the oncogene myc), and whose amplification
is associated with malignant transformation and poor
prognosis, may have contributed to the oncolytic effect
observed [84].
(iii) Lymphoma
Burkitt’s lymphoma is a sporadic form of lymphoma,
which is often associated with Epstein-Barr virus
(EBV) infection. Although current treatment
options led to improved survival in adults, an efficient
cure is not yet available and, as a result, innovativetreatments are needed. In this regard, H-1PV may
be a potential candidate since in vitro and in vivo
studies have demonstrated the ability of the virus
to efficiently kill Burkitt’s lymphoma-derived cell
lines (most likely through a necrotic mechanism
and irrespective of EBV positivity) and to induce
complete tumor destruction in severe combined
immunodeficient (SCID) mice, accompanied by
viral replication and spreading [85]. Furthermore,
diffuse large B cell lymphoma (DLBCL), cutaneous
T cell lymphoma (Cezary syndrome), large cell
immunoblastic lymphoma, T cell acute lympho-
blastic leukemia (T-ALL), and acute promyelocytic
leukemia cells were killed efficiently by H-1PV
in vitro; interestingly, oncolytic virus infection of
these cells was productive in most cases (Angelova
et al, unpublished observations).
(iv) Melanoma
Killing effects have been observed in human
melanoma-derived cell lines infected with H-1PV,
indicating that the virus may also be able to target
this tumor type. H-1PV-induced melanoma cell
death was found to be immunogenic, leading to
the activation of antigen-presenting cells and tumor-
specific cytotoxic T lymphocytes [64].
(v) Mammary carcinoma
Breast cancer is another potential tumor targetable by
H-1PV, as shown both in vitro and in a xenograft
mouse model [86,87]. Furthermore, short-term cultures
of patient-derived breast cancer cells were shown
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by the virus [86-89].
(vi) Pancreatic carcinoma
A number of studies have investigated the therapeutic
potential of H-1PV against pancreatic ductal adeno-
carcinoma, a cancer type classified among the most
frequent cause of cancer-related deaths, and for
which effective treatment options are still lacking.
Gemcitabine is a chemotherapeutic drug currently in
use for the treatment of advanced local and metastatic
pancreatic cancer. Unfortunately, resistance of cancer
cells to gemcitabine dramatically reduces the efficacy
of the therapy and causes tumor recurrence [90].
H-1PV cytotoxic effects have been reported in
pancreatic cancer-derived cell lines and in animal
tumor models, without being associated with sig-
nificant deleterious side effects [91]. Interestingly,
H-1PV could kill both gemcitabine-sensitive and
resistant cell lines. Moreover, the oncosuppressive
effects of H-1PV could be further enhanced by
combining the virus with gemcitabine, suggesting
an interesting novel combination option for the
treatment of pancreatic carcinomas. The suscepti-
bility of pancreatic cancer-derived cell lines to
H-1PV infection was reported to correlate with the
expression of functional SMAD4, a transcription
factor which is involved in the regulation of the
tumor growth factor β (TGF-β) signaling pathway
[92], and whose gene is mutated in about 50% of
pancreatic carcinomas. Mutations or deletions of
SMAD4 have been associated with a decrease in
the sensitivity of pancreatic cancer cells to H-1PV,
which was traced back to the involvement of
SMAD4 in parvovirus P4 promoter activation and
ensuing NS1 expression [93]. Furthermore, as
mentioned previously, H-1PV exerts immunostimula-
tory effects through the infection of pancreatic
carcinoma-derived cells. Although pancreatic cancer
generally exhibits low immunogenicity, it was shown
that pre-treatment of NK cells with interleukines
stimulated NK cell recognition of tumor cells. H-1PV
infection of pancreatic cancer cells further sensitized
these cells to NK cell-mediated killing by stimulating
the release of cytokines and chemokines known to
recruit immune cells to the tumor site, and by increas-
ing the expression of ligands to NK cell-activating
receptors on the cancer cell surface [94]. In a recent
study [68], the release of high-mobility group box
protein B1 (HMGB1) from H-1PV-infected pancreatic
ductal adenocarcinoma (PDAC) cells was reported,
providing further evidence of the immunogenic nature
of H-1PV-induced PDAC cell death. Importantly, this
virus-mediated danger signaling process was reinforced
by standard anti-PDAC cytotoxic treatments(gemcitabine), supporting the concept of H-1PV
inclusion in multimodal treatments for pancreatic
cancer patients. Furthermore, co-injection of recombin-
ant IFN-γ was shown in an orthotropic pancreatic
carcinoma model to enhance activation of macrophages
and splenocytes, virus spreading to metastatic sites and
animal survival, warranting clinical investigation of this
promising strategy [69].
(vii) Cervical carcinoma
Cervical cancer is the second most common
cancer in women. Although prevention screenings
have significantly reduced mortality, and the
vaccination program against human papillomaviruses,
the major cause of cervical cancer, is expected to
reduce tumor incidence among young women, the
prognosis for the advanced disease remains poor,
with a 1-year survival of only 15-20% [95]. H-1PV is a
promising therapeutic agent for the treatment of
cervical carcinoma. Indeed, it has been reported
that H-1PV infection induces tumor regression in
SCID mice implanted with the human cervical
cancer-derived HeLa cells, in a dose-dependent
manner and in correlation with viral gene expres-
sion [96]. Interestingly, our group recently showed
that H-1PV efficacy against cervical carcinomas
can be potentiated by combining the virus with
histone deacetylase (HDAC) inhibitors [13]. In
particular, sublethal doses of valproic acid (VPA)
synergistically enhanced H-1PV-induced killing
effects in cervical carcinoma cell lines. Remarkably,
in a HeLa xenograft rat model, H-1PV/VPA co-
treatment induced complete tumor regression
without causing adverse side effects at doses of
virus that were ineffective as a monotherapy. This
H-1PV/VPA cooperative effect was shown to be
associated, both in vitro and in vivo, with increased
induction of oxidative stress, DNA damage and
apoptosis, as well as with enhanced viral DNA
replication, gene expression and production. The
efficacy of the H-1PV/VPA combination was also
demonstrated in a range of pancreatic cancer-derived
cell lines and rodent xenograft models of human
pancreatic carcinomas, indicating that this combin-
ation may represent a promising approach also for
the treatment of this type of cancer.
(viii) Gastric carcinoma
H-1PV-induced killing of human gastric cancer
cells was found to follow the up- or downregula-
tion of the expression of a number of cellular
genes [97]. Recombinant NS1 expression was also
shown to reduce the tumorigenic potential of
poorly differentiated gastric cancer cells implanted
in nude mice, providing evidence that this viral
protein interferes with the growth of these cells
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antineoplastic effects of H-1PV on gastric tumors.
(ix) Hepatoma
H-1PV oncolytic effects have been reported in
hepatoma-derived cancer cell lines, in which virus
infection was associated with viral DNA replication,
gene expression and virus production. Importantly,
no cytotoxicity was observed in H-1PV-infected
normal primary hepatocytes [99]. Upon infection
with H-1PV, sensitive human hepatoma cells
showed a global repression of genes involved in cell
proliferation, growth and apoptosis [100]. Ex vivo or
in vivo infection with H-1PV also inhibited tumor
development from human hepatoma xenografts in
nude mice [101].
(x) Colon carcinoma
In comparison with the tumor types described
above, human colon cancer appears to exhibit lower
susceptibility to the oncolytic activity of H-1PV, as
suggested by the fact that infected colon carcinoma-
derived cell lines show little cytopathic effects and fail
to sustain efficient viral replication [102]. However,
it is noteworthy that H-1PV infection of colon
cancer cells potentiates their NK cell-mediated
killing by up-modulating the expression of NK
cell-activating receptor ligands displayed on the tumor
cells [66]. Therefore, although inefficient at inducing a
direct oncolytic effect in colon carcinoma, H-1PV
may still be of therapeutic value against this tumor by
enhancing the ability of infected colon carcinoma cells
to activate innate immune cells.
ParvOryx 01: the first clinical trial using an oncolytic
parvovirus
The preclinical evidence obtained in glioma cultures and
animal models provided the basis for the launching of a
first phase I/IIa clinical trial, named ParvOryx01, involving
patients with GBM.
Besides the above-mentioned preclinical evidence of
H-1PV anti-glioma effects, the ability of H-1PV to cross
the blood-brain barrier and infect intracerebral tumors
after systemic administration to rats gives hope for the de-
velopment of non-invasive, H-1PV-based treatments of
GBM [103]. The trial started in late 2011 and involves 18
adult patients diagnosed with GBM grade IV, recurring in
spite of chemo- and radio therapy. This is a phase I/IIa dose
escalation study aimed primarily at confirming H-1PV
safety, and secondarily at gathering preliminary evidence of
anticancer efficacy. The study design comprises two arms
differing in the first step of the treatment, namely intratu-
moral versus intravenous administration of half of the total
virus dose, and sharing the second step of the treatment,
namely tumor resection at day 10 and administration of the
remaining half of the total virus dose into the wall of theresection cavity [76]. The trial is still in progress, and no
clinical conclusions can be drawn at the present time be-
sides safety of H-1PV up to a dose of 109 infectious units
per patient. Biological monitoring is conducted by analysing
the patients’ bodily fluids and resected tumor. The results
of this accompanying research are intriguing, showing that
H-1PV achieves widespread infection of gliomas, also
after intravenous administration, and undergoes at least
limited replication and expression in neoplastic tissues.
Interestingly, this virus replication in some tumors is asso-
ciated with necrosis and massive infiltration with T cells,
including CTLs, some of which appear to be specific
for viral and glioma epitopes (unpublished results). We
trust that the further analysis of these surrogate markers
of efficiency, as well as clinical data, will warrant the
future extension of parvovirus clinical studies to subsequent
phases, including also second-generation RoPV-based
(combination) treatments.
Developing novel RoPV-based therapies with enhanced
anticancer efficacy
In recent years, H-1PV has been the subject of genetic
manipulations that aimed at increasing virus oncospeci-
ficity and anticancer efficacy in order to optimize the
therapeutic potential of RoPV-based treatments. Genetic
engineering of the H-1PV capsid proved to be a suitable
approach to increase virus specificity for cancer cells at
the level of cell recognition and entry. The above-
mentioned determinants of RoPV oncotropism indeed
operate at the intracellular level. In consequence, the
wild-type virus is able to enter most normal cells, which
undergo a cryptic or abortive infection that is clinically
unapparent but results in the sequestration and loss of a
major fraction of inoculated virions away from the
tumor target. In a first step, sites were identified on the
capsid, which were involved in binding to normal cellular
receptors, and whose modifications led to virus detarget-
ing, i.e. lack of uptake by normal cells. In a second step, a
site was identified within the viral capsid tolerating the
insertion of the RGD-4C cyclic peptide. This peptide rec-
ognizes αvβ3 and αvβ5 integrins, which are typically over-
expressed on cancer cells and angiogenic blood vessels,
and was used as a model ligand for virus retargeting to
these cells. Indeed, the RGD-4C-decorated virus showed
increased specificity for cancer cells, while retaining the
oncolytic potential of the parental virus [28]. This study
provided proof-of-concept demonstration of the possibil-
ity of minimizing parvoviral entry into normal cells for the
benefit of treatment safety and efficacy, and paved the way
for further retargeting either by grafting other peptidic
ligands of cancer-specific receptors (such as the epidermal
growth factor receptor overexpressed in gliomas [104]) or
by inserting peptide libraries to be used for in vitro and
in vivo screenings.
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into a replication-defective adenovirus vector genome,
with the aim of generating an adenovirus-parvovirus
chimera. The chimeric vector multiplied to high-titers,
thus allowing the large-scale production of parvoviral
DNA-containing particles, which is generally difficult to
achieve with current parvovirus production procedures,
rendering the chimera virus more suitable for clinical
applications. The parvoviral genome was efficiently re-
leased from the adenoviral DNA backbone in target can-
cer cells, leading to autonomous H-1PV replication,
cytotoxic effects and production of fully infectious par-
voviral particles. The adenoviral carrier allowed H-1PV to
be delivered into tumor cells originally resistant to direct
parvovirus entry, and to kill these cells under conditions
in which neither parental virus was efficient. While show-
ing this broader oncolytic activity, the adeno/parvoviral
chimera kept the innocuousness of its infectious parvo-
virus component for normal cells, thereby warranting fur-
ther (pre)clinical assessment in vivo [105]. Future studies
will be directed toward the development of a second gen-
eration of Ad-PV chimeras with improved anticancer
activity either by arming the chimera with proapoptotic
or immunostimulatory transgenes, or by improving its
cancer specificity by using retargeted Ad as a backbone.
Interestingly, the immunomodulatory effect of H-1PV
could be enhanced by arming the virus with specific
PAMPs, namely CpG motifs [106]. It remains to be ex-
plored whether other (immuno) regulatory elements could
be introduced into the RoPV genome, considering the fact
that the virus, owing to its limited packaging capacity,
does not tolerate the insertion of transgenes larger than a
few hundred nucleotides for infectivity to be retained.
It has been observed that cancer cell lines differ in their
sensitivity to RoPV infection, with some of them being
poorly permissive to virus replication and cytotoxicity. RoPV
replication in human cancer cells can be enhanced through
virus adaptation. Isolation of virus variants adapted for
efficient production and spreading in human glioma
cell cultures was recently achieved by serial passaging
H-1PV in semi-permissive glioma cells (Nuesch et al.
unpublished results).
As mentioned above, combinations of H-1PV with
physical (ionizing radiation) and chemical (gemcitabine,
temozolomide) cytotoxic agents, or with epigenetic modu-
lators (HDAC inhibitors) resulted in striking synergistic
oncolytic effects both in cell culture and animal models,
providing the preclinical proofs of concept needed to
move these protocols into the clinic. We anticipate that
future studies will be directed toward the identification of
other anticancer agents or therapeutic modalities (e.g. im-
munotherapy) that may act additively or synergistically
with the virus in eliminating cancer cells, reinforcing the
antineoplastic activity of the virus whilst keeping itsexcellent safety profile (see also next paragraph). This
advance may also allow a reduction of the therapeutic
dose to be used in cancer patients while maintaining or
even enhancing efficacy.
Future challenges
Oncolytic viruses are gaining momentum as a novel form
of anti-cancer therapy. As demonstrated in the numerous
pre-clinical models described above, RoPVs display strik-
ing oncosuppressive effects whilst being non-pathogenic
to humans. For the full potential of these anti-cancer
agents to be exploited, we believe that the development of
more complex treatment strategies, aimed at enhancing
virus replication, direct oncolytic activity and/or immuno-
logical adjuvant effects, will be necessary. Indeed, the vary-
ing susceptibility of tumor cell lines to RoPV replication
and cell killing observed in vitro indicates that further
optimisation of RoPV-based therapy is likely to be crit-
ical for the treatment of advanced human cancers
characterised by high intratumoral heterogeneity and
genomic instability.
Combination therapies
To this end, we anticipate that combination therapy using
agents that synergize with RoPVs, may hold the key for
maximizing anti-cancer effects. The permissiveness of a
given cancer cell for RoPV infection and replication is gov-
erned by an intricate set of virus/host interactions which,
as is the case with many OVs, remain largely unknown. A
more thorough understanding of the parvoviral life-cycle
and host factors implicated in it may reveal novel targets
for therapeutic intervention, thus guiding the development
of RoPV-based combination therapies with augmented
anti-neoplastic activity. The power of such rationally de-
signed combinations to reinforce RoPV therapy is exempli-
fied by the synergism observed between H-1PV and
HDAC inhibitors, following the discovery that acetylation
of NS1 enhances its cellular functions [13]. To efficiently
dissect the relationship between RoPVs and the host, one
particularly promising strategy is the high-throughput
RNAi screening (htRNAi), a platform which facilitates
genome-wide analysis of the cellular factors involved in
virus life-cycles [107]. When used for the first time to iden-
tify host factors that modulate Maraba virus-induced onco-
lysis, htRNAi revealed an unexpected synergistic target
(the ER stress response) for OV therapy, demonstrating
the capacity of this technology to direct effective combin-
ation treatments [108].
The above-mentioned rational design of combination
therapy requires prior knowledge of particular virus host
interactions. As an alternative approach, high-throughput
screening of drug and chemical libraries may be per-
formed in an unbiased fashion to identify compounds that
potentiate OV therapy. This approach has already shown
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of OV activity. For example, equilibrative nucleoside
transporter-1 (ENT1) antagonists were found to be potent
amplifiers of oHSV replication following a drug screening
to identify molecules that increased viral spread [109],
whilst a chemical library screen for compounds that sensi-
tise cancer cells to viral cytotoxicity revealed a previously
unidentified small molecule as a synergistic enhancer of
VSV-mediated cell killing [110].
More relevant disease models for proof-of-concept
validation
Following the identification of promising PV-drug com-
binations in vitro, their safety and efficacy must be cor-
roborated in vivo. Pre clinical validation of RoPV-based
therapies is traditionally performed using two classes of
in vivo systems: (i) xenograft models, generated from
the implantation of cultured human tumor cells into
immunocompromised rodents, and (ii) immunocompe-
tent syngeneic models, bearing tumors originating from
the same species. Despite providing valuable indications
of efficacy, both approaches carry significant drawbacks
that limit their utility as predictive tools of clinical out-
come: xenograft models will not reveal the positive or
negative consequences of the host immune response to
treatment, whilst results from syngeneic animal models
can be misleading since the behavior of the virus within
cells, as well as immune response towards it, may vary
considerably between species. Furthermore, tumors
established from cultured cell lines seldom recapitulate
the complexity or heterogeneity of those observed in
patients. For predicting the clinical outcome of novel
RoPV-based treatments and selecting the best combin-
ation therapies to move towards the clinic, patient-
derived tumor xenograft models are likely to be more
informative as they retain greater similarity to parental
tumors [111]. Considering the anticipated importance
of an immune-mediated component of therapy, the use
of novel ‘humanised’ animal models may also be of par-
ticular value for pre clinical RoPV validation, as evidenced
by a recent study of H-1PV oncolytic and immunostimu-
lating effects against PDAC [68]. Reconstituted animals
develop a functional human immune system whilst
permitting the engraftment of human tumor cells [112],
making them powerful tools for studying the immune
response during cancer therapy [113].
Upscaling of virus production
Another significant challenge facing the field, which may
hamper the successful translation of these therapeutics to
the clinic, is the large-scale production of RoPV-based
vectors in compliance with Good Manufacturing Practice
(GMP). To produce RoPV vectors at the quality and quan-
tity required to meet clinical demand, major efforts mustbe directed towards the search for more productive
packaging cell lines and optimisation of culture media and
growth conditions, as well as the improvement of purifica-
tion procedures. The development of high-yielding, scal-
able bioreactor platforms using cell lines growing in
suspension is also an important goal for reducing the con-
siderable costs of virus production.
Patient stratification
Looking forward, we believe that the identification of bio-
markers predictive of sensitivity/resistance to RoPV ther-
apy will also be a critical step towards its effective use in
clinical settings. With this knowledge, patients may be
screened for the presence of specific markers and selected
for “smart” clinical trials based upon their likelihood of
responding to treatment. Moreover, in those patient sub-
sets exhibiting certain features that could conceivably
compromise efficacy, outcome may be improved through
the rational application of combination therapy and/or the
use of engineered RoPVs. Figure 3 summarises the con-
cept that patients are stratified and RoPV-based treatment
regimens customised to individual needs.
Earlier-line virotherapy
The successful translation of laboratory results into effect-
ive cancer treatments requires more than just talented re-
searchers and inspired clinicians. Early-phase trials of
oncolytic viruses are typically conducted on patients with
advanced or recurrent cancers, for whom all other thera-
peutic options have failed. However, conventional first-line
treatments of some forms of cancer, including glioblastoma
multiforme, provide only modest benefit to the patients
and are often associated with severe adverse side-effects.
Furthermore, the ability of patients to mount a robust im-
mune response is often compromised at such late stages of
disease, which may prevent them from benefiting from the
immunostimulating action of RoPVs. Long-term thera-
peutic improvements may therefore be gained primarily by
patients treated at early stages of their disease. This raises a
delicate regulatory issue: should patients with aggressive
cancers, for which no curative therapies are currently avail-
able, have access to novel treatments at an earlier point
after diagnosis? While lying beyond the scope of this re-
view, this regulatory issue deserves more discussion.
Exciting results at the pre clinical level offer a tantaliz-
ing glimpse of the potential of oncolytic parvoviruses as
novel anti-cancer agents. However, the successful trans-
lation of these promising laboratory results into clinically
effective treatments is still in its infancy. We anticipate
that the ongoing clinical trial will provide valuable infor-
mation enabling the further exploitation of RoPV thera-
peutic properties, as well as revealing hurdles that may
limit efficacy. Overcoming these limitations represents a
challenge to be taken up first at the bench level. Guided
Figure 3 Towards individualized parvovirus-based treatments. A better understanding of PV-host interaction with identification of key
cellular factors playing a role in the PV-life cycle and in virus-mediated cytotoxicity may provide valuable hints for a more rational and efficient
use of PV-based therapies in clinical settings. Predictive tests may identify patients with a molecular portrait that makes them more likely to
benefit from virus treatment or targeted combination therapies.
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ling RoPV-host interactions and malignant progression,
we endeavor to develop next-generation RoPV-based
treatments with improved anticancer efficacy. This effort
will hopefully contribute to reinforce the impact of
RoPVs on the fight against this devastating disease.Conclusions
Oncolytic virotherapy of cancer has emerged as a prom-
ising alternative to toxic chemotherapy regimens. Among
a dozen oncolytic viruses presently tested at the clinical
level, rodent parvoviruses (and the H-1 parvovirus in
particular) attract considerable attention, due to their re-
markable natural oncoselectivity and lack of pathogen-
icity for humans. In the last two decades, an impressive
amount of preclinical data has been accumulated, show-
ing that H-1PV possesses both oncolytic and immunosti-
mulating properties. These give the virus a significant
cancer therapeutic potential, either alone or in combin-
ation with other agents (e.g. histone deacetylase inhibi-
tors), as revealed in several tumor models. Cancers
targeted by RoPVs include glioblastoma multiforme, the
most common and aggressive primary brain tumor in
humans. The first phase I/IIa clinical trial using an onco-
lytic parvovirus (H-1PV) was launched in 2011 for pa-
tients with recurrent GBM. We trust that this ongoingclinical study will pave the way for subsequent efficacy tri-
als, and prompt the development of next-generation
parvovirus-based anticancer therapeutics.
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